Advances in CAR ‐T therapy for small cell lung cancer

Small cell lung cancer (SCLC), a highly aggressive subtype of lung cancer, has limited treatment options and a poor prognosis for patients. Traditional treatments, including platinum-based drugs and etoposide chemotherapy, provide good initial responses but are highly susceptible to drug resistance, resulting in a markedly reduced long-term survival rate. In recent years, the success of chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies and its potential in the treatment of solid tumors have brought new hope for the treatment of SCLC. This article presents a review of the application of CAR-T cell therapy in SCLC, including an examination of the structural optimization of CAR-T cells, an analysis of therapeutic targets for SCLC, and a discussion of the latest progress in preclinical and clinical research. The objective of this study is to present novel insights and pioneering strategies for immunotherapy in SCLC, with the aim of advancing the field of tumor immunotherapy.